These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 27230923)

  • 61. Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter.
    Arakawa R; Ichimiya T; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Yasuno F; Kato M; Okubo Y; Suhara T
    J Psychiatr Res; 2009 Oct; 43(15):1219-23. PubMed ID: 19457493
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 18F-FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease.
    Kang Y; Henchcliffe C; Verma A; Vallabhajosula S; He B; Kothari PJ; Pryor KO; Mozley PD
    J Neuroimaging; 2019 Jan; 29(1):97-103. PubMed ID: 30230118
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
    Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D
    Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Deep learning based low-activity PET reconstruction of [
    Daveau RS; Law I; Henriksen OM; Hasselbalch SG; Andersen UB; Anderberg L; Højgaard L; Andersen FL; Ladefoged CN
    Neuroimage; 2022 Oct; 259():119412. PubMed ID: 35753592
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.
    Matuskey D; Worhunksy P; Correa E; Pittman B; Gallezot JD; Nabulsi N; Ropchan J; Sreeram V; Gudepu R; Gaiser E; Cosgrove K; Ding YS; Potenza MN; Huang Y; Malison RT; Carson RE
    Neuroimage; 2016 Apr; 130():241-247. PubMed ID: 26876475
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Validation of Noninvasive Tracer Kinetic Analysis of
    Bullich S; Barthel H; Koglin N; Becker GA; De Santi S; Jovalekic A; Stephens AW; Sabri O
    J Nucl Med; 2018 Jul; 59(7):1104-1110. PubMed ID: 29175981
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter--application to juvenile myoclonic epilepsy.
    Odano I; Varrone A; Savic I; Ciumas C; Karlsson P; Jucaite A; Halldin C; Farde L
    Neuroimage; 2012 Feb; 59(4):3582-93. PubMed ID: 22056530
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects.
    Kuikka JT; Tupala E; Bergström KA; Hiltunen J; Tiihonen J
    Eur J Nucl Med; 1999 Nov; 26(11):1486-8. PubMed ID: 10552092
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Roussakis AA; Politis M; Towey D; Piccini P
    Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Quantification of serotonin transporter availability with [11C]MADAM--a comparison between the ECAT HRRT and HR systems.
    Schain M; Tóth M; Cselényi Z; Stenkrona P; Halldin C; Farde L; Varrone A
    Neuroimage; 2012 Mar; 60(1):800-7. PubMed ID: 22227138
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults.
    Smith CT; San Juan MD; Dang LC; Katz DT; Perkins SF; Burgess LL; Cowan RL; Manning HC; Nickels ML; Claassen DO; Samanez-Larkin GR; Zald DH
    Transl Psychiatry; 2018 Dec; 8(1):269. PubMed ID: 30531858
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET.
    Fischer K; Sossi V; von Ameln-Mayerhofer A; Reischl G; Pichler BJ
    Neuroimage; 2012 Feb; 59(3):2413-22. PubMed ID: 21945469
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [
    Marner L; Korsholm K; Anderberg L; Lonsdale MN; Jensen MR; Brødsgaard E; Denholt CL; Gillings N; Law I; Friberg L
    EJNMMI Res; 2022 Sep; 12(1):56. PubMed ID: 36070114
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study.
    Ma Y; Dhawan V; Mentis M; Chaly T; Spetsieris PG; Eidelberg D
    Synapse; 2002 Aug; 45(2):125-33. PubMed ID: 12112405
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Relationship between regional gray matter volumes and dopamine D
    Kurose S; Kubota M; Takahata K; Yamamoto Y; Fujiwara H; Kimura Y; Ito H; Takeuchi H; Mimura M; Suhara T; Higuchi M
    Hum Brain Mapp; 2021 Aug; 42(12):4048-4058. PubMed ID: 34014611
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sertraline treatment influences [
    Justesen TEH; Borghammer P; Aanerud J; Hovind P; Marner L
    EJNMMI Res; 2023 May; 13(1):46. PubMed ID: 37221321
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I.
    Kim W; Tateno A; Arakawa R; Sakayori T; Ikeda Y; Suzuki H; Okubo Y
    Int J Neuropsychopharmacol; 2014 May; 17(5):697-703. PubMed ID: 24451483
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies.
    Jensen PS; Ziebell M; Skouboe G; Khalid U; de Nijs R; Thomsen G; Knudsen GM; Svarer C
    J Nucl Med Technol; 2011 Dec; 39(4):271-8. PubMed ID: 22072699
    [TBL] [Abstract][Full Text] [Related]  

  • 80. N-acetylcysteine decreases dopamine transporter availability in the non-lesioned striatum of the 6-OHDA hemiparkinsonian rat.
    Virel A; Johansson J; Axelsson J; Ericsson M; Laterveer R; Ögren M; Orädd G; Jakobson Mo S; Af Bjerkén S
    Neurosci Lett; 2022 Jan; 770():136420. PubMed ID: 34958912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.